Logo-ipp

Immunopathol Persa. 2021;7(1): e03. doi: 10.34172/ipp.2021.03

Review

Sphingosine 1 phosphate agonists (SPI); a potential agent to prevent acute lung injury in COVID-19

Sepideh Zununi Vahed 1 ORCID, Shahram Ghiyasvand 1, Seyed Mahdi Hosseiniyan Khatibi 1 ORCID, Bhargav Patel 2 ORCID, Mohammadali Mohajel Shoja 3, Ramin Tolouian 4 ORCID, Mohammadreza Ardalan 1 ORCID

Cited by CrossRef: 3

1- Teymouri S, Pourbayram Kaleybar S, Hejazian S, Hejazian S, Ansarin K, Ardalan M, Zununi Vahed S. The effect of Fingolimod on patients with moderate to severe COVID‐19. Pharmacology Res & Perspec. 2023;11(1) [Crossref]
2- Jamali E, Shapoori S, Farrokhi M, Vakili S, Rostamzadeh D, Iravanpour F, Tavakoli Oliaee R, Jafarinia M. Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review. Viral Immunology. 2023;36(6):368 [Crossref]
3- Al-kuraishy H, Batiha G, Al-Gareeb A, Al-Harcan N, Welson N. Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: the black side of the moon. Mol Cell Biochem. 2023;478(10):2271 [Crossref]